Investment Analysts’ Recent Ratings Updates for Charles River Laboratories International (CRL)

A number of research firms have changed their ratings and price targets for Charles River Laboratories International (NYSE: CRL):

• 12/21/2025 – Charles River Laboratories International was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/18/2025 – Charles River Laboratories International had its price target raised by analysts at Mizuho from $174.00 to $200.00. They now have a “neutral” rating on the stock.
• 12/15/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $210.00 to $215.00. They now have an “overweight” rating on the stock.
• 12/15/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $165.00 to $190.00. They now have a “neutral” rating on the stock.
• 12/15/2025 – Charles River Laboratories International was upgraded by analysts at Bank of America Corporation from a “neutral” rating to a “buy” rating. They now have a $225.00 price target on the stock.
• 12/13/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/1/2025 – Charles River Laboratories International was given a new $185.00 price target on by analysts at Morgan Stanley.
• 11/17/2025 – Charles River Laboratories International was given a new $200.00 price target on by analysts at Argus.
• 11/17/2025 – Charles River Laboratories International was upgraded by analysts at Argus from a “hold” rating to a “buy” rating.
• 11/11/2025 – Charles River Laboratories International had its price target raised by analysts at Morgan Stanley from $170.00 to $185.00. They now have an “equal weight” rating on the stock.
• 11/10/2025 – Charles River Laboratories International had its price target lowered by analysts at TD Cowen from $205.00 to $197.00. They now have a “buy” rating on the stock.
• 11/8/2025 – Charles River Laboratories International was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Baird R W from a “hold” rating to a “strong-buy” rating.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at JPMorgan Chase & Co. from $160.00 to $165.00. They now have a “neutral” rating on the stock.
• 11/6/2025 – Charles River Laboratories International had its price target raised by analysts at Barclays PLC from $195.00 to $210.00. They now have an “overweight” rating on the stock.
• 11/6/2025 – Charles River Laboratories International was upgraded by analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating. They now have a $199.00 price target on the stock, up previously from $178.00.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.